article thumbnail

Flashback: 2005 Tennessee Medicaid disenrollment led to increased crime, study finds

Fierce Healthcare

A new study, that draws parallels to current day redeterminations, delves into the relationship between mass Medicaid disenrollment in 2005 and how it may have led to violent crime.

116
116
article thumbnail

FDA Approves Nitisinone for Treatment of Alkaptonuria

Drug Topics

Patients were enrolled at the National Institutes of Health Clinical Center between April 2005 and March 2006, with 20 people receiving no treatment and 20 receiving nitisinone once daily. All patients were aged 18 to 65 years of age, except for 1 who was older than 65 years.

FDA 341
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

GLP-1s Effective as Adjunctive Therapy in Patients with T1D, Obesity | ADA 2025

Drug Topics

image credit: photoopus / stock.adobe.com The first GLP-1RA approved for use in the US was exenatide (Byetta) in 2005 for patients with type 2 diabetes (T2D). The abstract provides evidence of GLP-1RAs and their ability to interact with other necessary agents in diabetes care.

article thumbnail

Q&A: Lessons from the HHS secretary who ran Bush’s bird flu response

STAT

When he first heard about the avian flu outbreak in 2005, he had been secretary of health and human services in George W. WASHINGTON — Mike Leavitt is in the small club of government officials who’ve led an avian flu response. The experience is still fresh in his mind nearly two decades later. Read the rest…

143
143
article thumbnail

Zydus Pharmaceuticals (USA) Inc. Profile

Pharmacy Times

Zydus Pharmaceuticals (USA) Inc, has come a long way since its first commercial launch in August 2005.

123
123
article thumbnail

PLL Therapeutics appoints renowned ALS expert Philippe Corcia to scientific board

Pharmafile

Corcia, professor of neurology and head of the ALS Reference Centre in France since 2005, […] The post PLL Therapeutics appoints renowned ALS expert Philippe Corcia to scientific board appeared first on Pharmafile.

52
article thumbnail

STAT+: GLP-1s lower risk of 10 obesity-associated cancers, study shows

STAT

million patients with type 2 diabetes from 2005 to 2018 who were prescribed GLP-1s, insulin, or metformin. New research finds that the GLP-1 class of drugs — glucagon-like peptide receptor agonists — is more effective in mitigating the risk of 10 obesity-associated cancers than its type 2 diabetes drug alternatives.

145
145